Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Royalty Pharma

    - PMLiVE

    Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

    Over 800,000 people worldwide live with haemophilia

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Pfizer agrees pricing and distribution deal with US government

    The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

    - PMLiVE

    FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients

    One in ten children and adolescents in the US are affected by the neurological condition

    - PMLiVE

    Rain Free Days: A Migraine App Shaped by Real Experiences

    Rain Free Days® is a free migraine support app created by Teva, 11 London, and the migraine community. It helps users track symptoms, spot patterns, and access personalised resources like...

    11 London

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

    Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

    - PMLiVE

    FDA unveils new voucher programme to accelerate drug review process

    The programme is designed to reduce the review time for companies supporting US national interests

    - PMLiVE

    Pfizer shares ‘unprecedented’ survival results for Braftovi in colorectal cancer

    Around 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year

    - PMLiVE

    Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn

    The candidate is in clinical development for colorectal cancer, lung cancer and gynaecological tumours

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links